Publications, Pharmaceutical

Aptar Pharma discusses an antibody nasal spray for SARS-CoV-2

The delivery of antibodies by nasal spray has considerable potential for the treatment of SARS-CoV-2 and other viruses that enter the body via the upper respiratory system.

This paper describes work to develop a novel human antibody nasal spray as a prophylactic treatment against SARS-CoV-2. Formulations were developed at two protein concentrations and assessed for delivery using an Aptar VP3 nasal spray pump. Both formulations were shown to be suitable for nasal delivery in terms of pH, osmolality, and delivered droplet size; no evidence of protein agglomeration was observed as a result of spraying. Further studies are planned to investigate the stability of the developed products and to establish pharmacokinetics and pharmacodynamics.

Download Publication
8 Dec 2021

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

5 Jan 2023

Case Study – Unidose Nasal Spray Pump for Epilepsy

Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs o...

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
30 Nov 2022

Drug Repositioning – Benefits and Challenges for Lifecycle Mana...

Webinars, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
24 Nov 2022

Step to Success in Nose-to-Brain Drug Delivery

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
1 2 3 18
Back To Top